





Figure S1: Morphine Equivalent Daily Dose (MEDD) and Number of Adverse Events (AEs) according to the group and depending on sex. Note: * denotes $p < 0.05$ comparing men between groups, ** denotes $p < 0.01$ comparing women between groups. denotes $p < 0.05$ comparing women with men of the same group. # Denotes $p < 0.05$ comparing TAP vs. OXN, ## denotes $p < 0.01$ comparing TAP vs. OXN.

Table S1.- Multiple Linear regression of descriptive, clinical and pharmacological parameters with VAS pain, VAS relief, quality of life, and Morphine Equivalent Daily Dose as dependent variable in women and men groups.

Pain intensity	Model p-value R ²	Predictive variables	Beta coefficient (CI 95%)	p-value
Women	<0.001 0.377	Pain relief	-0.381 (-0.47-(-0.29))	<0.001
		Quality of life	-0.021 (-0.03-0.009)	<0.001
		Number of AE	0.147 (0.07-0.22)	<0.001
		Use of Neuromodulators	0.656 (0.17-1.14)	0.008
Men	<0.001 0.326	Pain Relief	-0.373 (-0.50-(-0.24))	<0.010
		Quality of life	-0.02 (-0.04-(-0.003))	0.023
		Number of AE	0.122 (0.01- 0.23)	0.032
		Use of Neuromodulators	-0.819 (-1.6-(-0.03))	0.040
MEDD				
Women	0.033	Pain relief	3.215 (-0.48-6.91)	0.045
	0.016	Number of AE	3.490 (0.431-6.548)	0.025
Pain relief				
Men	3.069x10 ⁻¹¹	Quality of life	0.029 (0.01-0.04)	0.001
	0.2441	Pain intensity	-0.400 (-0.54-(-0.25))	1.81x10 ⁻⁷
Women	2.2x10 ⁻¹⁶	Quality of life	0.031 (0.02-04)	2.51x10 ⁻⁶
	0.241	Pain intensity	-0.364 (-0.47(-0.26))	6.91x10 ⁻¹¹
Quality of life				
Women	5.5x10 ⁻¹⁶	Pain relief	2.07 (1.15-2.87)	5.87x10 ⁻⁶
	0.205	Pain intensity	-1.51 (--2.45(-0.57))	0.001
		AE	-1.13 (-1.80(--0.45))	0.001

Men	1.47x10 ⁻⁷ 0.198	Pain relief	2.049 (0.85-3.24)	0.0008
		Pain intensity	-1.306 (-2.58(-0.02))	0.045
		Number of AE	-1 (-1.92(-0.07))	0.034
		Antidepressant	-7.14 (-13.77(-0.52))	0.034

Table S2- Multiple Linear regression of descriptive, clinical, and pharmacological parameters with VAS pain, VAS relief and quality of life as dependent variable in women and men depending upon pharmacological treatment.

Regression Equation	β Coefficient	SE	T	Sig. T	95% CI for Exp (B)		R ²	F test	p

Adverse events	0.177	0.052	3.361	<0.001	0.072	0.281			
TAP Women pain relief									
Constant	5.877	0.882	6.662	<0.001	4.131	7.622			
Pain intensity	-0.522	0.085	-6.142	<0.001	-0.690	-0.354	0.362	36.93	<0.001
Quality of life	0.022	0.010	2.138	0.034	0.001	0.043			
TAP Women quality of life									
Constant	58.155	6.647	8.753	<0.001	45.033	71.336			
Pain intensity	-3.155	0.743	-4.190	<0.001	-4.586	-1.644	0.275	24.67	<0.001
Pain relief	1.511	0.707	2.138	0.034	0.113	2.910			
TAP Men pain intensity									
Constant	8.237	0.758	10.860	<0.001	6.710	9.764			
Quality of life	-0.049	0.014	-3.415	0.001	-0.079	-0.020	0.202	11.66	0.001
TAP Men pain relief									
Constant	1.315	0.862	1.526	0.133	-0.419	3.051			
Quality of life	0.049	0.016	2.702	0.009	0.011	0.078	0.137	7.302	0.009
TAP Men quality of life									
Constant	58.659	9.933	5.905	<0.001	38.652	78.665			
Pain intensity	-3.283	1.240	-2.648	0.011	-5.779	-0.786	0.253	7.635	0.001
Pain relief	1.992	1.134	1.756	0.061	-0.292	4.276			
OXN Women pain intensity									
Constant	10.322	1.086	9.503	<0.001	8.170	12.475			
Pain relief	-0.44	0.071	-5.779	<0.001	-0.556	-0.272			
Anxiolytics	1.139	0.453	2.514	0.013	0.241	2.038	0.293	15.38	<0.001
Age	-0.043	0.016	-2.632	0.009	-0.076	-0.010			
OXN Women pain relief									
Constant	4.684	0.851	5.499	<0.001	2.995	6.372			
Pain intensity	-0.481	0.089	-5.396	<0.001	-0.658	-0.304			
Quality of life	1.285	0.484	2.653	0.009	0.325	2.245	0.361	20.55	<0.001
Anxiolytics	0.040	0.010	4.017	<0.001	0.020	0.060			
OXN Women quality of life									
Constant	46.513	5.357	8.681	<0.001	35.893	57.133			
Pain relief	2.620	0.650	4.025	<0.001	1.329	3.910	0.294	15.01	<0.001

[illegible]